Where Will Pathologic Hip Fractures Go in a Value-based Hip Fracture Bundle?
Azeem Tariq MalikJohn H AlexanderSafdar N KhanThomas J ScharschmidtPublished in: The Journal of the American Academy of Orthopaedic Surgeons (2020)
Patients sustaining a pathologic/neoplastic hip fracture have a worse adverse event profile. Risk adjustment based on facture etiology will be necessary to ensure that providers taking care of pathologic/neoplastic fractures are appropriately reimbursed to minimize barriers to access of care for this vulnerable cohort.
Keyphrases
- hip fracture
- neoadjuvant chemotherapy
- end stage renal disease
- healthcare
- palliative care
- locally advanced
- chronic kidney disease
- ejection fraction
- quality improvement
- newly diagnosed
- prognostic factors
- peritoneal dialysis
- pain management
- squamous cell carcinoma
- affordable care act
- lymph node
- health insurance
- patient reported